Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Research Article

Sensitive HPLC Method to Support Pre-formulation Studies and to Determine Critical Quality Attributes of Therapeutic Contact Lenses Containing Dorzolamide Hydrochloride

Author(s): Harshilkumar Jani, Ketan Ranch*, Rahul Lalwani, Yashkumar Patel, Kunjan Bodiwala and Anuradha Gajjar

Volume 20, Issue 9, 2024

Published on: 08 November, 2024

Page: [994 - 1004] Pages: 11

DOI: 10.2174/0115734129341673241106101546

Price: $65

Abstract

Background: Dorzolamide hydrochloride (DRZ) is a carbonic anhydrase inhibitor used to treat glaucoma and ocular hypertension. Drug-eluting contact lenses, such as Acuvue Theravision ™ with Ketotifen, offer improved drug delivery and reduced side effects compared to eye drops. Drug-loaded nanoparticle-loaded contact lenses can sustain drug release and enhance comfort for extended wear.

Objectives: High buffer concentration and low pH increase the risk of damage to silica-bonded columns. Therapeutic contact lenses face challenges related to critical lens parameters, including the estimation of drug incorporation and release due to interference of lens matrix leaching. There is currently no analytical method available for estimating DRZ in contact lenses.

Methods: The HPLC method, which was developed and validated using ICH Q2 (R1) criteria, used a C18 column (250 mm × 4.6 mm, 5 μm) as a stationary phase and methanol:water (70:30 v/v) as the mobile phase. The detecting wavelength was 253 nm. Moreover, to support the efficiency of the developed method, the marketed formulation of DRZ eye drops, drug purity, and loading in contact lenses were analysed. The method was also employed to determine the Critical Quality Attributes (CQAs) of therapeutic contact lenses and drug release and drug leaching during the sterilization process.

Results: The developed HPLC method shows Rt for DRZ at 2.881 minutes with good linearity (r2 > 0.998) between 2-32μg/mL, precision (RSD < 2%), accuracy (Recovery > 99.5%), sensitivity, and specificity for quantifying DRZ in marketed formulations and therapeutic contact lenses. The developed method is devoid of any buffer or modifier in the mobile phase, making it safer for the stationary phase. This method mitigates the interference of lens matrix leaching, which induces an overestimation of DRZ. All the result for therapeutic contact lenses was found to be closely aligned with theoretically expected results, confirming the reliability of the developed HPLC method for therapeutic contact lenses.

Conclusion: This method is specific, accurate, and precise for quantifying DRZ in commercial formulations and newly developed therapeutic contact lenses. It effectively evaluates the critical quality attributes of these lenses, demonstrating their reliability for assessing their performance and ensuring quality in therapeutic applications.

Keywords: Dorzolamide hydrochloride, high performance liquid chromatography, therapeutic contact lenses, preformulation studies, nanoformulation, critical quality attributes.

Graphical Abstract
[1]
Government of India, Ministry of Health & Family Welfare. Indian Pharmacopoeia The Indian Pharmacopoeia Commission: Ghaziabad, 2018.
[2]
Desai, A.; Shukla, M.; Maulvi, F.; Ranch, K. Springer: Singapore, 2020; pp. Ophthalmic and otic drug administration: Novel approaches and challenges. In: Novel Drug Delivery Technologies; Misra, A.; Shahiwala, A., Eds.; 335-338.
[http://dx.doi.org/10.1007/978-981-13-3642-3_10]
[3]
Tian, B.; Bilsbury, E.; Doherty, S.; Teebagy, S.; Wood, E.; Su, W.; Gao, G.; Lin, H. Ocular drug delivery: Advancements and innovations. Pharmaceutics, 2022, 14(9), 1931.
[http://dx.doi.org/10.3390/pharmaceutics14091931] [PMID: 36145679]
[4]
Chawnani, D.; Ranch, K.; Patel, C.; Jani, H.; Jacob, S.; Al-Tabakha, M.M.; Boddu, S.H.S. Design and optimization of acetazolamide nanoparticle-laden contact lens using statistical experimental design for controlled ocular drug delivery. J. Biomater. Sci. Polym. Ed., 2024, 1-25.
[http://dx.doi.org/10.1080/09205063.2024.2391233] [PMID: 39155730]
[5]
Ahmed, S.; Amin, M.M.; Sayed, S. Ocular drug delivery: A comprehensive review. AAPS PharmSciTech, 2023, 24(2), 66.
[http://dx.doi.org/10.1208/s12249-023-02516-9] [PMID: 36788150]
[6]
Rykowska, I.; Nowak, I.; Nowak, R. Soft contact lenses as drug delivery systems: A review. Molecules, 2021, 26(18), 5577.
[http://dx.doi.org/10.3390/molecules26185577] [PMID: 34577045]
[7]
Li, C.C.; Chauhan, A. Modeling ophthalmic drug delivery by soaked contact lenses. Ind. Eng. Chem. Res., 2006, 45(10), 3718-3734.
[http://dx.doi.org/10.1021/ie0507934]
[8]
González-Chomón, C.; Concheiro, A.; Alvarez-Lorenzo, C. Soft contact lenses for controlled ocular delivery: 50 years in the making. Ther. Deliv., 2013, 4(9), 1141-1161.
[http://dx.doi.org/10.4155/tde.13.81] [PMID: 24024513]
[9]
Boddu, S.H.S.; Acharya, D.; Hala, V.; Jani, H.; Pande, S.; Patel, C.; Shahwan, M.; Jwala, R.; Ranch, K.M. An update on strategies to deliver protein and peptide drugs to the eye. ACS Omega, 2023, 8(39), 35470-35498.
[http://dx.doi.org/10.1021/acsomega.3c02897] [PMID: 37810716]
[10]
Maulvi, F.A.; Soni, T.G.; Shah, D.O. A review on therapeutic contact lenses for ocular drug delivery. Drug Deliv., 2016, 23(8), 3017-3026.
[http://dx.doi.org/10.3109/10717544.2016.1138342] [PMID: 26821766]
[11]
Johnson & Johnson vision care receives FDA approval for ACUVUE® theravision™ with ketotifen – World’s first and only drug-eluting contact lens. 2022. Available from: https://www.jjvision.com/press-release/johnson-johnson-vision-care-receives-fda-approval-acuvuer-theravisiontm-ketotifen(Accessed on: May 1, 2024)
[12]
Kumar, N.; Aggarwal, R.; Chauhan, M.K. Extended levobunolol release from Eudragit nanoparticle-laden contact lenses for glaucoma therapy. Future J. Pharm. Sci., 2020, 6(1), 109.
[http://dx.doi.org/10.1186/s43094-020-00128-9]
[13]
Maulvi, F.A.; Soni, T.G.; Shah, D.O. Extended release of timolol from ethyl cellulose microparticles laden hydrogel contact lenses. Open Pharm. Sci. J., 2015, 2(1), 1-12.
[http://dx.doi.org/10.2174/1874844901502010001]
[14]
Baghban, R.; Talebnejad, M.R.; Meshksar, A.; Heydari, M.; Khalili, M.R. Recent advancements in nanomaterial-laden contact lenses for diagnosis and treatment of glaucoma, review and update. J. Nanobiotechnology, 2023, 21(1), 402.
[http://dx.doi.org/10.1186/s12951-023-02166-w] [PMID: 37919748]
[15]
Maulvi, F.A.; Choksi, H.H.; Desai, A.R.; Patel, A.S.; Ranch, K.M.; Vyas, B.A.; Shah, D.O. pH triggered controlled drug delivery from contact lenses: Addressing the challenges of drug leaching during sterilization and storage. Colloids Surf. B Biointerfaces, 2017, 157, 72-82.
[http://dx.doi.org/10.1016/j.colsurfb.2017.05.064] [PMID: 28577503]
[16]
Maulvi, F.A.; Patel, A.R.; Shetty, K.H.; Desai, D.T.; Shah, D.O.; Willcox, M.D.P. Chitosan nanoparticles laden contact lenses for enzyme-triggered controlled delivery of timolol maleate: A promising strategy for managing glaucoma. Drug Deliv. Transl. Res., 2024, 14(11), 3212-3224.
[http://dx.doi.org/10.1007/s13346-024-01543-8] [PMID: 38407770]
[17]
Erk, N. Simultaneous determination of dorzolamide HCL and timolol maleate in eye drops by two different spectroscopic methods. J. Pharm. Biomed. Anal., 2002, 28(2), 391-397.
[http://dx.doi.org/10.1016/S0731-7085(01)00627-6] [PMID: 11929684]
[18]
Erk, N. Rapid and sensitive HPLC method for the simultaneous determination of dorzolamide hydrochloride and timolol maleate in eye drops with diode-array and UV detection. Pharmazie, 2003, 58(7), 491-493.
[PMID: 12889534]
[19]
Thangabalan, B.; Kahsay, G.; Eticha, T. New RP-HPLC method development and validation for dorzolamide in ophthalmic dosage form. J. Anal. Methods Chem., 2018, 2018, 1-5.
[http://dx.doi.org/10.1155/2018/4596141] [PMID: 30275997]
[20]
Sharma, N.; Rao, S.S.; Reddy, A.M. A novel and rapid validated stability-indicating UPLC method of related substances for dorzolamide hydrochloride and timolol maleate in ophthalmic dosage form. J. Chromatogr. Sci., 2012, 50(9), 745-755.
[http://dx.doi.org/10.1093/chromsci/bms025] [PMID: 22562819]
[21]
Mathrusri Annapurna, M.; Narendra, A.; Deepika, D. Development and validation of RP-HPLC method for simultaneous determination of dorzolamide and timolol maleate in pharmaceutical dosage forms. J. Drug Deliv. Ther., 2012, 2(2)
[http://dx.doi.org/10.22270/jddt.v2i2.120]
[22]
Havele, S.S.; Dhaneshwar, S.R. Stability-indicating HPTLC-densitometric method for estimation of dorzolamide hydrochloride in eye drops. ISRN Anal. Chem., 2012, 2012, 1-7.
[http://dx.doi.org/10.5402/2012/414075]
[23]
Kalyankar, G.G.; Patel, J.; Bodiwala, K.B.; Lodha, S.R.; Mistry, V. Development and validation of first order UV derivative spectroscopy method for simultaneous estimation of cilnidipine and chlorthalidone in their combined tablet dosage form. Int. J. Pharma Sci., 2019, 10(2), 101-111.
[24]
Lotfy, H.M.; Hegazy, M.A.; Rezk, M.R.; Omran, Y.R. Novel spectrophotometric methods for simultaneous determination of timolol and dorzolamide in their binary mixture. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2014, 126, 197-207.
[http://dx.doi.org/10.1016/j.saa.2014.02.005] [PMID: 24607469]
[25]
Palabiyik, I.M.; Caglayan, M.G.; Onur, F. Multivariate optimization and validation of a CE method for simultaneous analysis of dorzolamide hydrochloride and timolol maleate in ophthalmic solution. Chromatographia, 2011, 73(5-6), 541-548.
[http://dx.doi.org/10.1007/s10337-010-1901-6]
[26]
Erk, N. Voltammetric and HPLC determination of dorzolamide hydrochloride in eye drops. Pharmazie, 2003, 58(12), 870-873.
[PMID: 14703963]
[27]
The United States Pharmacopoeia. The United States pharmacopeia: USP 30; The National formulary: NF 25; United States Pharmacopeial Convention: Rockville, MD, 2017.
[28]
Zammataro, A.; Saletti, R.; Civiale, C.; Muccilli, V.; Cunsolo, V.; Foti, S. Simultaneous quantification of carteolol and dorzolamide in rabbit aqueous humor and ciliary body by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2010, 878(9-10), 807-814.
[http://dx.doi.org/10.1016/j.jchromb.2010.01.041] [PMID: 20153987]
[29]
Constanzer, M.L.; Chavez, C.M.; Matuszewski, B.K. Low level determination of dorzolamide and its de-ethylated metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. J. Pharm. Biomed. Anal., 1997, 15(7), 1001-1008.
[http://dx.doi.org/10.1016/S0731-7085(96)01935-8] [PMID: 9160268]
[30]
Maltese, A.; Bucolo, C. Rapid high-performance liquid chromatographic assay of dorzolamide in rabbit aqueous humor. Biomed. Chromatogr., 2002, 16(4), 274-276.
[http://dx.doi.org/10.1002/bmc.138] [PMID: 11933028]
[31]
Claessens, H.A.; van Straten, M.A.; Kirkland, J.J. Effect of buffers on silica-based column stability in reversed-phase high-performance liquid chromatography. J. Chromatogr. A, 1996, 728(1-2), 259-270.
[http://dx.doi.org/10.1016/0021-9673(95)00904-3]
[32]
Toffoletto, N.; Saramago, B.; Serro, A.P. Therapeutic ophthalmic lenses: A review. Pharmaceutics, 2020, 13(1), 36.
[http://dx.doi.org/10.3390/pharmaceutics13010036] [PMID: 33379411]
[33]
Desai, D.T.; Maulvi, F.A.; Desai, A.R.; Shukla, M.R.; Desai, B.V.; Khadela, A.D.; Shetty, K.H.; Shah, D.O.; Willcox, M.D.P. In vitro and in vivo evaluation of cyclosporine-graphene oxide laden hydrogel contact lenses. Int. J. Pharm., 2022, 613, 121414.
[http://dx.doi.org/10.1016/j.ijpharm.2021.121414] [PMID: 34952149]
[34]
Maulvi, F.A.; Patil, R.J.; Desai, A.R.; Shukla, M.R.; Vaidya, R.J.; Ranch, K.M.; Vyas, B.A.; Shah, S.A.; Shah, D.O. Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation. Acta Biomater., 2019, 86, 350-362.
[http://dx.doi.org/10.1016/j.actbio.2019.01.004] [PMID: 30625414]
[35]
Kim, J.; Peng, C.C.; Chauhan, A. Extended release of dexamethasone from silicone-hydrogel contact lenses containing vitamin E. J. Control. Release, 2010, 148(1), 110-116.
[http://dx.doi.org/10.1016/j.jconrel.2010.07.119] [PMID: 20691228]
[36]
Desai, A.R.; Maulvi, F.A.; Pandya, M.M.; Ranch, K.M.; Vyas, B.A.; Shah, S.A.; Shah, D.O. Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: in vitro and in vivo evaluation. Biomater. Sci., 2018, 6(6), 1580-1591.
[http://dx.doi.org/10.1039/C8BM00212F] [PMID: 29708242]
[37]
Bodiwala, K.B.; Shah, J.; Sureja, D.K.; Dhameliya, T.M.; Khadela, A. Generation of predictive models for oxidative degradation kinetics of dapagliflozin with the applications of DOE and stability indicating HPLC method. Int. J. Chem. Kinet., 2022, 54(12), 712-725.
[http://dx.doi.org/10.1002/kin.21608]
[38]
Loftsson, T.; Jansook, P.; Stefánsson, E. Topical drug delivery to the eye: Dorzolamide. Acta Ophthalmol., 2012, 90(7), 603-608.
[http://dx.doi.org/10.1111/j.1755-3768.2011.02299.x]
[39]

© 2025 Bentham Science Publishers | Privacy Policy